Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial

2018 ◽  
Vol 174 (2) ◽  
pp. 433-442 ◽  
Author(s):  
O. Nanni ◽  
◽  
D. Amadori ◽  
A. De Censi ◽  
A. Rocca ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Trial ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Line Treatment ◽  
Phase 2 ◽  
First Line ◽  
Phase 2 Clinical Trial ◽  
Randomized Phase 2 ◽  
First Line Treatment

Capecitabine-Based Chemoendocrine Combination as First-Line Treatment for Metastatic Hormone-Positive Metastatic Breast Cancer: Phase 2 Study

2020 ◽  
Vol 20 (3) ◽  
pp. 228-237 ◽  
Author(s):  
Noha Rashad ◽  
Thoraya Abdelhamid ◽  
Samia A. Shouman ◽  
Hanan Nassar ◽  
Mervat A. Omran ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Line Treatment ◽  
Phase 2 ◽  
First Line ◽  
Phase 2 Study ◽  
First Line Treatment

Targeting HSP90 in breast cancer: Enchant-1 (NCT01677455) phase 2 proof of concept study of ganetespib in first-line treatment of women with metastatic breast cancer.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. TPS665-TPS665 ◽  
Author(s):  
David A. Cameron ◽  
Neil Spector ◽  
Javier Cortes ◽  
Max S. Mano ◽  
Jean-Luc Re Canon ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Line Treatment ◽  
Phase 2 ◽  
Proof Of Concept ◽  
First Line ◽  
Concept Study ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document